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INTRODUCTION
Knowledge of infection, hygiene, and nutrition has improved 
tremendously in comparison to the past, and antibiotics have 
developed remarkably. Nevertheless, hospital-acquired infec-
tions remain an issue, especially for patients in the Intensive 
Care Unit (ICU) and those under prolonged hospitalization. 
Pathogens resistant to antimicrobial agents are another 
emerging issue. According to the Centers for Disease Control 
and Prevention, gram negative bacteria accounted for the 
most urgent and serious microorganisms, such as carbapen-
em-resistant Enterobacteriaceae, Acinetobacter, and Pseudo-
monas aeruginosa.1-3
Burkholdria cepacia (B. cepacia) has emerged as another 
important bacterium cause of hospital-acquired infections. 
The bacterium is known formerly as Pseudomonas cepacia, a 
gram negative aerobic, glucose, non-fermenting, motile bacil-
lus. Immunocompromised and hospitalized patients are es-
pecially susceptible to this infection, leading to severe bacte-
remia that results in death.4 Studies also report its growth in 
endocarditis among drug addicts, in patients with prosthetic 
cardiac valves, in eye infections following surgical procedures, 
and in infections of the central nervous system. Once colo-
nized with a specific strain, replacement of the original strain 
with another is infrequent.5 B. cepacia can cause severe dis-
ease in humans with underlying disease, such as cystic fibro-
sis and chronic granulomatous disease (CGD).5,6  Fortunately, 
since cystic fibrosis and CGD are very rare in Korea, B. cepacia 
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infection is not usually a great concern. 
B. cepacia infection is not a common source of infection in 
adult and pediatric patients. However, in 2014, B. cepacia 
growth was confirmed more frequently in pediatric blood sam-
ples than in any other year. Therefore, to assess the possibility 
that B. cepacia has become another important source of noso-
comial infection, we analyzed clinical characteristics of B. cepa-
cia infection in pediatric patients in our hospital over the course 
of the past ten years.
MATERIALS AND METHODS
A retrospective study was performed in patients with blood 
isolates of B. cepacia from January 2004 to December 2014 in 
our hospital. 
The BacT/ALERT 3D (bioMérieux, Inc., Durham, NC, USA) 
blood culture system was used. Isolates were identified using 
the VITEK 2 system with GP and GN cards. An antimicrobial 
susceptibility test (AST) was performed via a broth microdilu-
tion test using the VITEK 2 system with P625, N211, and N212 
cards. AST interpretation was determined using Clinical and 
Laboratory Standard Institute (CLSI) guidelines; CLSI recom-
mended testing with ceftazidime, minocycline, meropenem, 
and cotrimoxazole in 2010.7
Since not all samples were available, we constructed a den-
drogram for B. cepacia from the sputum of three children and 
four adults only. The main spectrum profile (MSP) showing 
the highest score was selected from each isolate and was in-
cluded to construct the dendrogram using the statistical tool-
box in MATLAB 7.1 integrated in the matrix-assisted laser de-
sorption/ionization (MALDI) Biotyper 2.0 software (Bruker 
Daltonics GmbH, Leipzig, Germany). Based on the principle 
that identification score reflects the agreement of the spectra 
with the standard Acinetobacter baumannii database entry, 
the MSP profile showing the highest score implies that the 
specific spectra represents the most typical aspects of a certain 
strain from the database. This selection of the highest score 
marking spectra was necessary, especially when highly similar 
strains were studied because several mass spectral features re-
lated to limited reproducibility of the method might eclipse 
mass spectral differences between the strains. Test strain clon-
ality was determined with cut-off values at a distance of 250.8 
Instead of pulsed-field gel electrophoresis or whole genome 
sequencing, the gold standard for confirming clonality, we 
used the MALDI TOF Mass Spectrometry method.9
Patient clinical data were obtained retrospectively from elec-
tronic medical records. This study was approved by the Insti-
tutional Review Board (IRB) in our hospital (IRB No. 4-2015-
0540). 
RESULTS
Over the 10-year period, a total of 14 pediatric patients and 55 
adult patients were identified as having B. cepacia bacteremia 
(Table 1). In the years 2005, 2009 and especially in 2014, high-
er rates of B. cepacia bacteremia were observed in pediatric 
patients (Fig. 1). Although the increasing patterns in 2009, 
2013, and 2014 were similar, there were few differences in an-
nual incidence between adults and children. The overall inci-
dence of B. cepacia bacteremia in pediatric patients was lower 
than that in adult patients. 
There was no difference between genders in children. Most 
children had underlying disease except for one patient. Un-
derlying diseases included cancer (4/14), congenital heart 
disease (4/14), immunodeficiency, such as CGD (1/14), and 
prematurity (2/14). One previously healthy pediatric patient 
who had pneumonia and a history of treatment in the ICU 
also had B. cepacia bacteremia. Three out of 14 pediatric pa-
tients had positive B. cepacia intravenous catheter tip cultures 
simultaneously with blood culture.
Among adults, more male than female patients had B. cepa-
cia bacteremia (1.72:1). Almost all adult patients had underly-
ing disease. They were mostly oncology patients (40/55) and 
patients with cardiovascular problems (13/55). Only two had 
a history of simple surgery. 
Most of the pediatric patients had undergone ICU care (12/ 
14). Twelve of the patients with ICU care were initially due to 
underlying disease or right after cardiac surgery, not due to B. 
cepacia infection. In adult patients, 47% underwent ICU care 
(26/29), fewer that for the children.
Eleven pediatric patients had their sputum cultures exam-
ined, of which five children had the same strain of B. cepacia 
grown from the blood samples; the other six children had 
other strains but not B. cepacia. Three did not get sputum cul-
tures because there was no pneumonia. Among the adult pa-
tients, only five patients had the same strain of B. cepacia 
grown from the blood samples. Two patients had multidrug 
resistance who stayed in the oncologic general ward without 
history of ICU care. Though they are isolated in the same 
month, the sensitivity patterns of antibiotics were different, 
and thus, they were thought to be different pathogens. Antibi-
otics were used properly based on the antibiotics sensitivity 
results (Table 2). Only one patient was administered co-timox-
azole for treatment, and 11 patients including the previously 
mentioned patients used meropenem. Four children expired 
despite treatment. Only two of the patients were thought to 
have expired by direct effect of B. cepacia bacteremia. Another 
one patient had multiple gram negative bacterial growth in 
their blood samples, and could not predicate B. cepacia as the 
direct cause of death. The remaining patient expired due to un-
derlying cardiac disease after cardiac surgery. Among the adults, 
20 patients expired, 13 due to the direct effect of B. cepacia. 
Since not all samples were available for study, we only gath-
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ered seven samples of B. cepacia from sputum, three from 
children and four from adults. Patients B, E, and F were chil-
dren. Patients A, B, C, and G had a history of ICU care in March 
2014, and patient D had a history of ICU care in August 2014. 
Patients E and F had a history of pediatric cardiovascular ICU 
(PCCU) care in March and August (Fig. 2). We were able to find 
two clonalities; those were each isolated in March and August 
in the ICU and PCCU.
DISCUSSION
Our hospital data showed that B. cepacia infection was not 
common over the past ten years. The total number of cases 
with B. cepacia bacteremia was 69, and of these, about 20% 
were pediatric cases with low incidence. As in adult patients, 
pediatric patients continually showed B. cepacia infection in 
our hospital. We do not think B. cepacia infection is increasing 
in pediatric populations. However, in 2014, there were five cas-
es of B. cepacia bacteremia in pediatric patients, which was 
unlike the rate in other years. We are unable to explain the rea-
son for the increased incidence of B. cepacia in year 2014. How-
ever, physicians should be aware of this pathogen as a cause 
of the hospital infection in immunocompromised patients 
and in previously healthy pediatric patients with a history of 
ICU care. 
According to other reports and studies, B. cepacia mainly 
causes problems in patients with cystic fibrosis or immuno-
deficient patients, such as CGD, rather than in immunocom-
petent patients. In our case, there was one patient with CGD 
and expired due to B. cepacia sepsis. It can cause mortality in 
over 90% of pediatric cystic fibrosis patients who have pulmo-
Fig. 1. Annual incidence of B. cepacia infection in our hospital. B. cepacia, Burkholderia cepacia.
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Table 2. Microbial Sensitivity of B. Cepacia Isolated from 14 Patients
Patient ID Ceftazidime Levofloxacin Meropenem Minocycline Tetracycline Cotrimoxazole
1 S R S Not done R I
2 S R S Not done R I
3 S S S Not done R S
4 I I R Not done R S
5 S S S Not done S S
6 S S S S Not done S
7 I I S I Not done S
8 S I S S Not done R
9 S S S S Not done S
10 S S S S Not done S
11 S S S S Not done S
12 I S S S Not done S
13 R I R R Not done S
14 I I R R Not done R
B. cepacia, Burkholderia cepacia; S, susceptible; I, intermediate; R, resistant.
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nary damage, after colonization and being transferred to the 
blood stream. In the ICU setting and in treatment with cathe-
ters or similar devices, this infection can lead to morbidity and 
mortality. In our study, mortality cases were suspected to have 
expired due to infection with B. cepacia. Fortunately, in Korea, 
as cystic fibrosis and CGD are rare conditions, B. cepacia is 
not much of a concern to physicians. However, as ICU care 
and catheter or device treatment is increasing, the importance 
of B. cepacia infection is also increasing. In 14 cases of B. cepa-
cia bacteremia, 13 cases had underlying disease, and 12 had a 
history of ICU care. This is consistent with other reports.10-14 
Although immune status was not assessed during the study pe-
riod, cardiac surgery, chemotherapy, and prematurity can cause 
immunosuppressive conditions, and this may lead to sepsis. 
When comparing data for the children and the adults, there 
were no significant differences, except for ICU care. As many 
of the adult patients had signed do not resuscitate (DNR) doc-
uments, patients were not admitted to the ICU and main-
tained treatment in the general ward.
Five of the 11 cases with sputum culture results showed the 
same strain of B. cepacia grown from blood samples. This sug-
gests that colonization with B. cepacia in the airway can cause 
bacteremia and lead to morbidity and mortality, although 
there is no exact evidence that B. cepacia in the airway is a 
pathogen or not. Nevertheless, there is no effective method 
for eradication of colonized B. cepacia. Therefore, hospital en-
vironment and health care hygiene are still the most impor-
tant issues.
Therapeutic options for B. cepacia are unfortunately limited 
because many strains of this organism exhibit high levels of 
resistance to many antimicrobial agents in vitro, which may 
be intrinsic to certain cases. Studies report up to 50.4% resis-
tance to every antibiotic tested, indicating that multidrug re-
sistant isolates are not uncommon.5,15 In our study, B. cepacia 
isolated from five cases all reported sensitivity to antibiotic 
agents. Only one patient showed resistance to ceftazidime, 
three to meropenem, and two to co-trimoxazole. 
The antimicrobial option most commonly used in B. cepacia 
infection is co-trimoxazole (trimethoprim/sulfamethoxazole). 
Co-trimoxazole is also the prophylactic drug of choice for 
CGD. There is some hurdle to the use of co-trimoxazole, since 
allergic or hypersensitivity reactions, intolerance, and resis-
tance may be observed in patients receiving co-trimoxazole.15 
Our CGD case was also using cefixime for prophylactic mea-
sure instead of co-trimoxazole due to a history of allergic reac-
tion to co-trimoxazole.
In this study, many different antimicrobials were tested. In-
terestingly, patients who survived responded efficiently to the 
prescribed antibiotics. Even after removal of the catheter or 
device, we could not isolate B. cepacia from the blood of pa-
tients anymore, without changing antibiotics. This might sug-
gest that B. cepacia infection in patients without underlying 
immunocompromised disease may be controlled well only 
with removal of contaminated catheters or devices. The pre-
vailing thought has been that removal of a contaminated cath-
eter or device should be essential for the control of B. cepacia 
infection, which is the principal treatment for catheter infec-
tions. 
As B. cepacia bacteremia was increased in both adults and 
children, there was no obvious association between the two 
groups, though the trend seemed to be similar. According to the 
dendrogram results, we suspect that there may be a reservoir in 
our hospital. We do not know whether the pathogens isolated 
from children are from adult patients or contrary pathogens 
isolated from adults are form children. As we do not have a sep-
arate pediatric ICU and share the same space with adult pa-
tients, we can say that children can share the same hospital in-
fection. Accordingly, this suggests the importance of sustainable 
infection control and hygiene. 
The limitation of this study is that it was a retrospective study 
from a single center. The number of study subjects was also 
too small. The strength of this study is that we reviewed data for 
a ten-year period and B. cepacia bacteremia in pediatric pa-
tients. Since not much data exists regarding B. cepacia in Ko-
rea, especially in pediatric patients, more data should be col-
lected and analyzed. 
Although there were not many cases in our hospital, aware-
ness of colonization and effective therapy of B. cepacia infec-
tion is needed, as such an infection can cause mortality and 
morbidity. Also, infection control and monitoring are important, 
especially in patients under prolonged hospital admission.
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